title: Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity.
authors.forename: Fotios
authors.initials: F
authors.lastname: Loupakis
authors.forename: Alfredo
authors.initials: A
authors.lastname: Falcone
authors.forename: Gianluca
authors.initials: G
authors.lastname: Masi
authors.forename: Anna
authors.initials: A
authors.lastname: Fioravanti
authors.forename: Robert S
authors.initials: RS
authors.lastname: Kerbel
authors.forename: Mario
authors.initials: M
authors.lastname: Del Tacca
authors.forename: Guido
authors.initials: G
authors.lastname: Bocci
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab